论文部分内容阅读
目的:研究肝细胞癌患者IL- 6、IL- 2 、sIL- 2R 的变化和意义。方法:分别采用ABS- ELISA 法、双抗体夹心ELISA 法对40 例肝癌患者进行了IL- 6 、IL- 2 、sIL- 2R 的测定,并与26 例肝炎肝硬化和66 例健康献血员进行了对照。结果:肝细胞癌( HCC) 患者血清IL- 6 、sIL- 2R 水平明显升高,而IL- 2 水平明显低于正常对照(NC)组( P< 0.01) ,HCC 组的IL- 6 水平高出正常10 倍以上, 较肝硬化组明显升高( P< 0.01) , 临床晚期肝癌患者的IL- 6 水平显著高于临床早期。IL- 6 与sIL- 2R 显著正相关,而与IL- 2 无相关关系。结论:肝细胞癌患者存在免疫功能紊乱和低下、淋巴因子网络失衡, 这与其病理生理机制有关, 也为临床上HCC 应用IL- 2 治疗提供了理论依据。IL- 6 的显著增高有助于HCC 的早期诊断。
Objective: To study the changes and significance of IL-6, IL-2, and sIL-2R in patients with hepatocellular carcinoma. Methods: 40 patients with hepatocellular carcinoma were tested for IL-6, IL-2, and sIL-2R by ABS-ELISA and double antibody sandwich ELISA, respectively, and were compared with 26 patients with hepatitis cirrhosis and 66 healthy donors. Control. Results: Serum levels of IL-6 and sIL-2R were significantly elevated in patients with hepatocellular carcinoma (HCC), while IL-2 levels were significantly lower than those in the normal control (NC) group (P<0.01). IL-6 levels in the HCC group were high. More than 10 times normal, significantly higher than the cirrhosis group (P < 0.01), clinically advanced liver cancer patients IL-6 levels significantly higher than early clinical. There was a significant positive correlation between IL-6 and sIL-2R, but no correlation with IL-2. Conclusion: There are immunological dysfunctions in patients with hepatocellular carcinoma and the imbalance of lymphokine network, which is related to its pathophysiological mechanisms. It also provides a theoretical basis for clinical application of IL-2 therapy in HCC. The significant increase in IL-6 contributes to the early diagnosis of HCC.